Shane Schaffer
Chairman and CEO, Cingulate Inc. (biotech industry)
Shane Schaffer is the co-founder, chairman, and chief executive officer of Cingulate Therapeutics, based in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is dedicated to developing and managing innovative branded pharmaceutical products. Its focus spans from Attention Deficit/Hyperactivity Disorders (ADHD) to other areas such as anxiety disorders and insomnia.
Extensive Pharmaceutical Expertise
He has amassed 25 years of experience in the pharmaceutical industry, specializing in drug development and commercialization. His strategic leadership and entrepreneurial approach in various business aspects, including product launches, brand planning, and market development, have established him as a prominent figure in the biopharmaceutical and marketing arenas.
Educational Journey
He completed his Doctor of Pharmacy at the University of Kansas in 1999 and further honed his skills with a post-doctoral fellowship at Rutgers University's College of Pharmacy. He worked at Pfizer Worldwide Marketing and Morris Plains during this time, gaining substantial professional experience.
Pfizer Worldwide Marketing, New York, NY
While at Pfizer, he served as a Marketing Manager, spearheading the development of pre-launch strategies and initiating the Global Communications Intranet to streamline communications between medical and marketing teams. He also helped establish the Pfizer Medical and Academic Partnership in Pain Management.
Morris Plains, New Jersey
He was tasked as project manager and external research manager in Morris Plains. In these roles, he led advanced sales and product launch training for femhrt®. He also managed Phase IV Medical Research for all marketed brands at the Parke-Davis Medical and Scientific Affairs division.
Professional Achievements
His career trajectory includes significant roles at Pfizer, Novartis, and Sanofi, where he developed and commercialized several billion-dollar brands.
Novartis Pharmaceuticals Corporation
At Novartis, he managed the Ritalin® LA / Focalin™ product lines, significantly enhancing the company's ADHD franchise through his leadership from inception to execution.
Ritalin® LA & Focaline
His launches of Ritalin® LA and Focaline exceeded expectations, achieving high market penetration and rapid awareness. His excellence in multiple product launches earned him the Novartis Business Excellence Award.
ADHD Franchise
In 2004, he oversaw all operations of the ADHD franchise, launching an innovative faculty development program that trained over 1,400 speakers in just three months.
Sanofi-Aventis
He continued his impactful work at Sanofi Aventis, particularly during the company's merger and joint venture phases. He significantly influenced brand management for Avapro and Avalide and led promotional strategies.
Entrepreneurial Ventures
After leaving Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant, overseeing business development. In 2009, he founded Sabre Scientific Solutions, LLC, offering consultancy services to the pharmaceutical and biotechnology sectors.
Cingulate Therapeutics LLC
His enduring passion for addressing ADHD and anxiety disorders inspired him to establish Cingulate Therapeutics LLC in 2013. As CEO, he drives the company's mission to innovate drug delivery technologies for these conditions.
Indegene: A Strategic Partnership
Cingulate has partnered with Indegene to market its phase-3 oral ADHD medication CTx-1301, aiming to enhance patient care by reducing dependency on traditional medications.
Future Plans
The company is on track to submit a new drug application to the FDA by mid-2025 for its main ADHD asset, CTX-1301, marking a significant milestone in its development.
Philanthropic Commitment
Beyond his professional life, he is actively involved with the Folds of Honor Charity, providing educational support to children affected by the loss or disability of military parents.